new version V2017

direct antithrombins
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

atrial fibrillation

dabigatran
PETRO (150mg), 2007dabigatran 150mgwarfarin standard dose Exploratory -
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard dose Risk of bias Suggesting NCT00262600
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard dose Risk of bias SuggestingNCT00262600
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002ximelagatranwarfarin standard dose Risk of bias -
SPORTIF III, 2003ximelagatranwarfarin standard dose Risk of bias Suggesting
SPORTIF V, 2005ximelagatranwarfarin standard dose Low risk of bias Suggesting

thrombosis prevention

dabigatran
RE-NOVATE 2dabigatran 220mgenoxaparinhip surgery Low risk of bias NegativeNCT00657150
RE-NOVATE (220mg), 2007dabigatran 220mgenoxaparinhip surgery Low risk of bias NegativeNCT00168818
RE-NOVATE (150mg), 2007dabigatran 150mgenoxaparinhip surgery Low risk of bias Negative NCT00168818
RE-MODEL (220mg), 2007dabigatran 220mgenoxaparin (europe regimen)knee surgery Low risk of bias Negative
RE-MODEL (150mg), 2007dabigatran 150mgenoxaparin (europe regimen)knee surgery Low risk of bias Negative
RE-MOBILIZE (220mg), 2008dabigatran 220mgenoxaparin (US regimen)knee surgery Low risk of bias Negative
RE-MOBILIZE (150mg), 2008dabigatran 150mgenoxaparin (US regimen)knee surgery Low risk of bias Negative
ximelagatran
Phase II (Heit), 2001ximelagatranEnoxaparinNegative
METHRO I, 2002ximelagatranDalteparinNegative
METHRO II, 2002ximelagatranDalteparinSuggesting
METHRO III, 2002ximelagatranEnoxaparinNegative
Platinum (Colwell), 2003ximelagatranEnoxaparinNegative
EXPRESS, 2003ximelagatranEnoxaparinSuggesting



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons